Suche Medizinische Publikationen
Suche Abbildungen und Grafiken
Medizinprodukte - Labortechnik
Antidotarium (Stand 2012)
Phytokodex (Stand 2012)
Endoskopie in Österreich (Stand 2010)
Kardiologie in Österreich (Stand 2006)
Osteologie in Österreich (Stand 2016)
Fachbücher
Patientenliteratur
Mueck AO, Heuberger H, Seeger H, Wallwiener D Comparison of Valsartan With Candesartan on Their Possible Protection From Atherosclerosis Journal of Clinical and Basic Cardiology 2001; 4 (4): 297-299 PDF Summary Overview
| ||||||||||
Figure/Graphic 3: AII-Antagonisten - Atherosklerose Changes in PAI-1 concentration in endothelial cell cultures from human coronary artery after addition of angiotensin II alone (10 microM), angiotensin (10 microM) + candesartan, and angiotensin (10 microM) + valsartan as percentage of control value = (100 %). (means +/- SD, triplicates from 2 different experiments, * p < 0.05, ** p < 0.01 vs A II; A II = angiotensin II; Can = candesartan; Val = valsartan) |
Figure/Graphic 3: AII-Antagonisten - Atherosklerose
Changes in PAI-1 concentration in endothelial cell cultures from human coronary artery after addition of angiotensin II alone (10 microM), angiotensin (10 microM) + candesartan, and angiotensin (10 microM) + valsartan as percentage of control value = (100 %). (means +/- SD, triplicates from 2 different experiments, * p < 0.05, ** p < 0.01 vs A II; A II = angiotensin II; Can = candesartan; Val = valsartan) |